The aim of this study is to determine the effect of electroacupuncture on central obesity and fatty liver in postmenopausal women.
Their ages will be ranged between 50 and 60 years old.
Their body mass index will be ranged from 30-40 kg/m2.
SGOT more 40 U/L.
SGPT more 40 U/L.
Cancer.
Concomitant cardiovascular disorders.
Respiratory, renal and liver dysfunction.
Parallel
Medical treatment
DrugAll women in both groups will adhere to the same medication (orlistat) as prescribed by the gynecologist for 12 weeks.
Hypocaloric diet
Other interventionAll women in both groups will be instructed to follow the same hypocaloric diet, as prescribed by a certified nutrition specialist, with a daily caloric intake of 1,200 kcal for a duration of 12 weeks.
Electroacupuncture
Other interventionWomen in the experimental group only will undergo electroacupuncture three times per week for 12 weeks. Treatment will be delivered in the supine position using sterile needles inserted at eight standardized acupoints associated with central obesity and weight regulation, with insertion depths of 10-25 mm. Low-frequency electrical stimulation (2 Hz, 0.5 ms) will be applied to the abdominal region for 30 minutes per session.
Body Mass Index (BMI)
BMI will be calculated as weight in kilograms divided by height in meters squared (kg/m²). Height will be measured using a stadiometer, and BMI will be assessed at baseline and post-intervention. BMI serves as a primary outcome as it provides a standardized indicator of overall obesity and treatment-related changes in adiposity.
Waist Circumference
Waist circumference will be measured at the narrowest point between the xiphoid process and the iliac crest at the end of gentle expiration, with participants standing. This measure directly reflects central obesity and is therefore considered a primary outcome.
Hip Circumference
Hip circumference will be assessed at the level of maximum circumference over the femoral trochanters.
Waist-to-Hip Ratio (WHR)
WHR will be calculated by dividing waist circumference by hip circumference. This index reflects fat distribution and cardiometabolic risk, making it a primary outcome for central obesity assessment.
Total Cholesterol (TC)
Fasting venous blood samples will be collected from the antecubital vein at baseline and after the 12-week intervention period. Serum will be separated by centrifugation within 8 hours and stored at -20°C until analysis. TC will be assessed using standardized enzymatic laboratory methods.
Triglycerides (TG)
TC will be quantified from serum samples obtained via antecubital venipuncture before and after the 12-week treatment program. Samples will be centrifuged within eight hours of collection and stored at -20°C until analysis.
Low-Density Lipoprotein Cholesterol (LDL)
LDL levels will be determined from serum samples drawn from the antecubital fossa of each participant prior to and following the 12-week intervention period. Collected samples will be centrifuged within eight hours and preserved at -20°C for subsequent laboratory analysis.
High-Density Lipoprotein Cholesterol (HDL)
HDL-C will be quantified from venous blood samples collected at the antecubital fossa before and after the 12-week electroacupuncture protocol, following centrifugation within eight hours and storage at -20°C.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
